All In Biotech

Drug Trial Radar · NCT07394452

Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects

A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TJ0113 Capsules Administered Orally as Single Dose, Multiple Doses, and Doses in the Fed State in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Aug 4, 2023

Primary completion

Feb 5, 2024

Study completion Apr 3, 2024

Sponsor

Lead sponsor
Hangzhou PhecdaMed Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study included three clinical studies, namely a single ascending dose (SAD) study, a multiple ascending dose (MAD) study, and a high-fat diet food effect (FE) study.

Conditions

  • Healthy Subjects

Interventions

  • TJ0113 CapsulesDrug

    Participants will receive oral administration of TJ0113.

  • PlaceboOther

    Participants will receive oral administration of Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after single oral administration in SAD studyTime frame: Within 12 days after the last administration
  2. Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after multiple oral administration in MAD studyTime frame: Within 12 days after the last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Xiaoshan hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.